Mizoribine selectively attenuates monocyte chemoattractant protein‐1 production in cultured human glomerular mesangial cell: A possible benefit of its use in the treatment of lupus nephritis

Aizawa, Tomomi; Imaizumi, Tadaatsu; Tsuruga, Kazushi; Watanabe, Shojiro; Chiba, Yuki; Matsumiya, Tomoh; Yoshida, Hidemi; Tanaka, Hiroshi

doi:10.1111/nep.12171

Cited by 5 publications

(3 citation statements)

References 23 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, no worsening of the serum creatinine level was noted in the 3-year post-marketing surveillance study conducted previously [9]. MZR exhibits a nephroprotective effect and is widely indicated for the treatment of primary nephrotic syndrome [21,22]. Therefore, it is unlikely that MZR impairs renal function.…”

Section: Renal Functionmentioning

confidence: 89%

Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results

Takeuchi

Okada

Yoshida

et al. 2017

Modern Rheumatology

View full text Add to dashboard Cite

Objectives: To understand the status of mizoribine use in patients with lupus nephritis (LN) and to collect safety-and efficacy-related data on 2-year treatment with mizoribine. Methods: A continuous survey was conducted between March 2010 and July 2015.Results: The analysis set included 559 patients (mean age 39.5 years, females 82.6%, mean duration of systemic lupus erythematosus (SLE) 8.4 years, mean duration of LN 5.9 years). Renal function was satisfactory for 6 months, but worsened from 12 months, with significant worsening at 24 months. By the ACR 2006 remission criteria (eGFR >60), at 24 months, 26.5% of patients achieved complete remission, and 63.3% achieved complete or partial remission. The urine protein to creatinine ratio decreased significantly. The SLE Disease Activity Index 2000 score decreased significantly at 12 and 24 months. Overall, 98 (17.5%) patients experienced 124 adverse drug reactions (ADRs); 3.6% experienced serious ADRs. Mizoribine was used with a steroid in 99.3% and an immunosuppressant in 51.2%; tacrolimus was used in 43.8%. The oral steroid dosage decreased from baseline to 24 months. The incidence of ADRs was not significantly different with concomitant tacrolimus use. Conclusions:The results suggest that long-term mizoribine is safe and effective, even when used with tacrolimus.ARTICLE HISTORY

show abstract

Section: Renal Functionmentioning

confidence: 89%

Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results

Takeuchi

Okada

Yoshida

et al. 2017

Modern Rheumatology

View full text Add to dashboard Cite

show abstract

“…Thus, TFP treatment significantly reduced blood urea nitrogen and serum creatinine levels in lupus mice without apparent side effects ( 134 ). Mizoribine (MZR) is a selective inhibitor of the inosine monophosphate dehydrogenase and a key enzyme in the de novo pathway of guanine nucleotides ( 135 ). MZR downregulates MCP-1 at both mRNA and protein levels in human MCs treated with poly (I:C), which is associated with the pathogenesis of LN ( 135 ).…”

Section: The Contribution Of Mc-related Therapeutics To Clinical Trea...mentioning

confidence: 99%

“…Mizoribine (MZR) is a selective inhibitor of the inosine monophosphate dehydrogenase and a key enzyme in the de novo pathway of guanine nucleotides ( 135 ). MZR downregulates MCP-1 at both mRNA and protein levels in human MCs treated with poly (I:C), which is associated with the pathogenesis of LN ( 135 ). ALW (ALWPPNLHAWVP), a peptide with 12 amino acids, inhibits the binding of polyclonal anti-dsDNA antibodies to MCs.…”

Section: The Contribution Of Mc-related Therapeutics To Clinical Trea...mentioning

confidence: 99%

Mesangial cell: A hub in lupus nephritis

et al. 2022

View full text Add to dashboard Cite

Lupus nephritis (LN) is a severe renal disease caused by the massive deposition of the immune complexes (ICs) in renal tissue, acting as one of the significant organ manifestations of systemic lupus erythematosus (SLE) and a substantial cause of death in clinical patients. As mesangium is one of the primary sites for IC deposition, mesangial cells (MCs) constantly undergo severe damage, resulting in excessive proliferation and increased extracellular matrix (ECM) production. In addition to playing a role in organizational structure, MCs are closely related to in situ immunomodulation by phagocytosis, antigen-presenting function, and inflammatory effects, aberrantly participating in the tissue-resident immune responses and leading to immune-mediated renal lesions. Notably, such renal-resident immune responses drive a second wave of MC damage, accelerating the development of LN. This review summarized the damage mechanisms and the in situ immune regulation of MCs in LN, facilitating the current drug research for exploring clinical treatment strategies.

show abstract

Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1 in human mesangial cells

et al. 2014

View full text Add to dashboard Cite

show abstract

Mizoribine selectively attenuates monocyte chemoattractant protein‐1 production in cultured human glomerular mesangial cell: A possible benefit of its use in the treatment of lupus nephritis

Abstract: Mizoribine itself selectively attenuated the expression of MCP-1 both mRNA and protein levels in MCs treated with poly IC; that is, a possible model of 'pseudoviral' infection, which may be involved in the pathogenesis of lupus nephritis.

Cited by 5 publications

References 23 publications

Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results

Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results

Mesangial cell: A hub in lupus nephritis

Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1 in human mesangial cells

Contact Info

Product

Resources

About